FDA 483 - Biocon Biologics Limited - September 03, 2025

During an inspection conducted from August 26th to September 3rd, 2025, the FDA identified significant deficiencies at Biocon Biologics Limited, a drug substance manufacturer in Bengaluru, India. The inspection report, known as an FDA Form 483, detailed observations primarily related to facility maintenance, equipment sanitation, and the quality management system, indicating a failure to adhere to Current Good Manufacturing Practices (cGMP).

Key issues included inadequate sanitation and maintenance within Grade C and D manufacturing areas, evidenced by standing liquid puddles and soiled cleaning equipment. Equipment cleanliness was also a concern, with visible rust and unaddressed leaks on manufacturing equipment, including Laminar Air Flow units. Furthermore, dynamic airflow studies for critical equipment were deficient, lacking evaluation of routinely used materials and observed air currents. The quality system demonstrated a failure to thoroughly investigate Out-of-Specification (OOS) results, specifically regarding microbial contamination, by not conducting retrospective reviews of similar recurring incidents.

Biocon Biologics Limited is required to respond to these observations by thoroughly investigating the root causes of each deficiency, implementing robust corrective and preventive actions, and demonstrating sustained compliance with cGMP regulations to ensure product quality and patient safety.